Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

Race CEO and Managing Director Dr Daniel Tillett speaks with Proactive Australia about a major clinical milestone in RC220's development. 

RC220 is the new formulation of the company's lead drug candidate, bisantrene. Race is currently running a Phase 1 clinical trial exploring RC220's safety, tolerability and pharmacokinetic data, plus the maximum tolerated combined dose of RC220 with doxorubicin.

After activating the lead trial site, Southside Cancer Care, Race has announced that the first patient for this trial has been successfully and safely dosed. Watch the interview below for more details on this announcement. Full repoort on Proactive can be accessed here. 

RC220 advances: Race Oncology hits key dosing milestone